Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 13/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 11/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22609136 | 0.78 | BRAF (0.48) | BRAFKITDDR1KDM4E | |
| SCHEMBL21646384 | 0.77 | KIT (0.40) | BRAFKITDDR1DDR2 | |
| SCHEMBL25424901 | 0.75 | PDE4B (0.43) | BRAFKITDDR1 | |
| SCHEMBL25124479 | 0.75 | DYRK1A (0.41) | ADRA2AADRA2BADRA2CEGLN2 | |
| SCHEMBL8448727 | 0.74 | KIT (0.36) | BRAFKITDDR1KDM4E | |
| SCHEMBL25239960 | 0.72 | KIT (0.46) | BRAFKITDDR1DDR2 | |
| SCHEMBL9729655 | 0.71 | KIT (0.38) | KITDDR1DDR2KDM4E | |
| SCHEMBL21618264 | 0.70 | ALDH1A1 (0.36) | BRAFKITDDR1KDM4E | |
| SCHEMBL24071012 | 0.70 | ALDH1A1 (0.36) | BRAFKITDDR1KDM4E | |
| SCHEMBL30686789 | 0.70 | MAPT (0.34) | BRAFKITDDR1DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | BRAF 3433/4885KIT 4884/4885DDR1 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.